Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 clinical trial of Pixavir marboxil (TG-1000)

Next Previous
Trial Profile

Phase 3 clinical trial of Pixavir marboxil (TG-1000)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pixavir (Primary)
  • Indications Influenza virus infections
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 28 Oct 2025 New trial record
  • 26 Aug 2025 According to a TaiGen Biotechnology media release, preliminary data were compiled and incorporated into the phase III clinical trial plan, which was submitted to the CDE for review during a communication meeting on the 25th.
  • 26 Aug 2025 According to a TaiGen Biotechnology media release, company has submitted phase III clinical trial plan to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for review and preparation for subsequent clinical trials.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top